Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Merck Patent Gesellschaft MIT Beschrankter Haftung

Roche Diagnostics Gmbh

Zentaris Ag

Bayer Animal Health Gmbh

Marcus Koppitz

Gerhard Siemeister

Philip Lienau

Benjamin Bader

Antje Margret Wengner

Dirk Kosemund

Ulrich Klar

Hans Briem

Stefan Prechtl

Julien Lefranc

Ulf Bömer

Rolf Bohlmann

Knut Eis

Ulrich Lücking

Hans Schick

Wilhelm Bone

Lars Wortmann

Rolf Jautelat

Roland Neuhaus

Volker Schulze

Duy Nguyen

Jens Nagel

Simon Holton

Nico Bräuer

Horst Kessler

Andrea Rotgeri

Hartmut Schirok

Tobias Marquardt

Holger Siebeneicher

Detlef Stöckigt

William Johnston Scott

Alfred Jonczyk

Wolfgang Schwede

Simon Lawrence Goodman

Anne Mengel

Elisabeth Pook

Ulrich Bothe

Ursula Mönning

Kenneth Jay Shaw

Olaf Peters

Clara Christ

Stuart Ince

Manfred Schmitt

Olaf Prien

Franz Von Nussbaum

Joanna Grudzinska-Goebel

Dieter Moosmayer

Uwe Eberspächer

Horst Irlbacher

Michaele Peters

Christof Wegscheid-Gerlach

Ulrich Weidle

Adam James Davenport

Viktor Magdolen

Antonius Ter Laak

Beate Diefenbach

Oliver Martin Fischer

Reinhard Nubbemeyer

Tobias Heinrich

Klaus Paulini

Holger Steuber

Antje Rottmann

Jens Schröder

Ildiko Terebesi

Anne-Marie Godinho-Coelho

Shelley Anne Parrott

Roman Hillig

Henrik Dahllöf

Christoph Riemer

James Lindsay Carr

Michael Brüning

Gernot Langer

Hans Peter Muhn

Bertolt Kreft

Robert James Townsend

Andrea Wagenfeld

Heinrich Graeff

Bernhard K&ouml;nig

Nina Connelly Ursinyova

Markus B&uuml;rgle

Florian Prinz

Holger Hess-Stump

Joszef Bálint

William Scott

Ulrich Lucking

Nico Brauer

Hans (deseased) Schick

Ulf BÖMER

Philipp Lienau

Hassan Y Harb

Ashley Eheim

Antje-Margret Wengner

Christof Wegscheidt-Gerlach

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R, Rand Rare as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients. 

Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

The present invention relates to novel benzimidazole derivatives of the general formula (I), to processes for their preparation and to their use for preparing pharmaceutical compositions for the treatment of disorders and indications associated with the EP4 receptor.

Benzimidazole derivatives as EP4 ligands

The present invention relates to substituted Pyridyl-cycloalkyl-carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis. 

Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis proliferative of diseases, as well as to intermediate compounds useful in the preparation of said compounds. 

Triazolopyridines

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. 

Substituted triazolopyridines

The present invention relates to substituted imidazopyridazine compounds of general formula I in which R, Rand A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted imidazopyridazines

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

The present invention relates to imidazopyrazine compounds of general Formula (I): in which X, R, R, R, R, R, R, R, and Rare as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds. 

Imidazopyrazines

Growing community of inventors

Berlin, Germany

Marcus Koppitz